Identification of a novel long-acting 4’-modified nucleoside reverse transcriptase inhibitor against HBV

Nobuyo Higashi-Kuwata,Sanae Hayashi,Hiroki Kumamoto,Hiromi Ogata-Aoki,Debananda Das,David Venzon,Shin-Ichiro Hattori,Haydar Bulut,Mai Hashimoto,Masaki Otagiri,Nobutoki Takamune,Naoki Kishimoto,David Davis,Shogo Misumi,Masakazu Kakuni,Yasuhito Tanaka,Hiroaki Mitsuya

Journal of Hepatology（2021）

引用 23|浏览38

暂无评分

摘要

•E-CFCP potently reduces HBV viremia without significant toxicity in human liver chimeric mice.•E-CFCP efficiently penetrates into and is tri-phosphorylated in human hepatocytes.•E-CFCP represents the first reported long-acting NRTI with potent anti-HBV activity.

查看译文

关键词

HBV,Long-acting anti-HBV therapeutic,NRTI,Drug-resistant HBVs,Human-liver-chimeric mice

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要